Form 4: Brainstorm Cell Therapeutics CEO Lebovits Increases Stake in Company

Chaim Lebovits, President and CEO of Brainstorm Cell Therapeutics, recently acquired 50,000 shares of common stock through direct purchases.

Summary

• Chaim Lebovits, the President and CEO of Brainstorm Cell Therapeutics, has reported changes in his beneficial ownership of the company's stock.
• On May 21, 2024, Lebovits acquired 25,000 shares of common stock at a price of $0.579 per share.
• On May 22, 2024, he acquired another 25,000 shares at $0.64 per share.
• Following these transactions, Lebovits directly owns 1,149,865 shares of common stock.
• He may also be deemed the beneficial owner of 2,000,847 indirectly held shares through ACCBT Corp. (1,933,794 shares) and ACC International Holdings Ltd. (67,053 shares).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the CEO's increased investment in the company, which signals confidence. However, it's important to consider the overall context of the company's performance and industry trends.

Positives

• The CEO's purchase of shares could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Insider buying is often seen as a positive signal, suggesting that a company's leadership believes the stock is undervalued.

Stakeholder Impact

• Shareholders may view the CEO's stock purchase as a positive signal.

Key Dates

Keywords

Brainstorm Cell Therapeutics, BCLI, Chaim Lebovits, Stock, Beneficial Ownership, SEC Form 4